Selective Inhibition of Soluble TNF using XPro1595 Improves Hippocampal Pathology to Promote Improved Neurological Recovery Following Traumatic Brain Injury in Mice
Authors:
- 1 November 2023
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in CNS & Neurological Disorders - Drug Targets
- Vol. 22 (9) , 1378-1390
Abstract
Aims: To determine the efficacy of XPro1595 to improve pathophysiological and functional outcomes in a mouse model of traumatic brain injury (TBI). Background: Symptoms associated with TBI can be debilitating, and treatment without off-target side effects remains a challenge. This study aimed to investigate the efficacy of selectively inhibiting the soluble form of TNF (solTNF) using the biologic XPro1595 in a mouse model of TBI. Objectives: Use XPro1595 to determine whether injury-induced solTNF promotes hippocampal inflammation and dendritic plasticity and associated functional impairments. Methods: Mild-to-moderate traumatic brain injury (CCI model) was induced in adult male C57Bl/6J WT and Thy1-YFPH mice, with XPro1595 (10 mg/kg, S.C.) or vehicle being administered in a clinically relevant window (60 minutes post-injury). The animals were assessed for differences in neurological function, and hippocampal tissue was analyzed for inflammation and glial reactivity, as well as neuronal degeneration and plasticity. Results: We report that unilateral CCI over the right parietal cortex in mice promoted deficits in learning and memory, depressive-like behavior, and neuropathic pain. Using immunohistochemical and Western blotting techniques, we observed the cortical injury promoted a set of expected pathophysiology’s within the hippocampus consistent with the observed neurological outcomes, including glial reactivity, enhanced neuronal dendritic degeneration (dendritic beading), and reduced synaptic plasticity (spine density and PSD-95 expression) within the DG and CA1 region of the hippocampus, that were prevented in mice treated with XPro1595. Conclusion: Overall, we observed that selectively inhibiting solTNF using XPro1595 improved the pathophysiological and neurological sequelae of brain-injured mice, which provides support for its use in patients with TBI.Keywords
All Related Versions
Funding Information
- Virginia Commonwealth Neurotrauma Initiative (FP00001476)
- NIH-NCI Cancer Center (P30 CA016059)
This publication has 97 references indexed in Scilit:
- Etanercept Attenuates Traumatic Brain Injury in Rats by Reducing Brain TNF-αContents and by Stimulating Newly Formed NeurogenesisMediators of Inflammation, 2013
- Genetic deletion of TNF receptor suppresses excitatory synaptic transmission via reducing AMPA receptor synaptic localization in cortical neuronsThe FASEB Journal, 2011
- Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelinationBrain, 2011
- Tumor necrosis factor‐α synthesis inhibitor, 3,6′‐dithiothalidomide, reverses behavioral impairments induced by minimal traumatic brain injury in miceJournal of Neurochemistry, 2011
- Peripheral Nerve Injury Leads to Working Memory Deficits and Dysfunction of the Hippocampus by Upregulation of TNF-α in RodentsNeuropsychopharmacology, 2011
- Genetic Analysis of the Role of Tumor Necrosis Factor Receptors in Functional Outcome after Traumatic Brain Injury in MiceJournal of Neurotrauma, 2010
- Structural Plasticity and Hippocampal FunctionAnnual Review of Psychology, 2010
- HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damageNature Neuroscience, 2009
- Alterations in Blood-Brain Barrier Permeability to Large and Small Molecules and Leukocyte Accumulation after Traumatic Brain Injury: Effects of Post-Traumatic HypothermiaJournal of Neurotrauma, 2009
- Oxidative stress and modification of synaptic proteins in hippocampus after traumatic brain injuryFree Radical Biology and Medicine, 2008